Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Completed 77Terminated 28Unknown 15Active not recruiting 14Recruiting 11Withdrawn 3Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Carboplatin 75Cisplatin 73Bevacizumab 64Radiotherapy 57Drug Therapy 56Capecitabine 56tislelizumab 54Oxaliplatin 54Gemcitabine 46toripalimab 45Paclitaxel 45Specimen Handling 43sintilimab 39pembrolizumab 39anlotinib 38Cyclophosphamide 33130-nm albumin-bound paclitaxel 32Magnetic Resonance Spectroscopy 27Injections 27camrelizumab 26Pemetrexed 26Surgical Procedures, Operative 25lenvatinib 23Docetaxel 23Biopsy 23apatinib 22Etoposide 22Immune Checkpoint Inhibitors 21S 1 (combination) 20Fluorouracil 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × Dasatinib × Clear all
NCT07269470 2026-05-05

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡